Abstract
Oncolytic viruses (OVs) preferentially infect and kill cancer cells. Additionally, OV-induced immune responses subvert cancer-associated immunosuppression and promote antitumor immunity. We have recently demonstrated that the complementation of oncolytic virotherapy with gemcitabine accentuates its immunostimulatory effects, hence exerting superior antineoplastic activity.
| Original language | English |
|---|---|
| Article number | e27622 |
| Journal | OncoImmunology |
| Volume | 3 |
| Issue number | 1 |
| DOIs | |
| Publication status | Published - 2014 |
Bibliographical note
Funding Information:This work was supported by the research grants from the Canadian Institute of Health Research (CIHR), Terry Fox Research
ASJC Scopus Subject Areas
- Immunology and Allergy
- Immunology
- Oncology
Access to Document
Other files and links
Fingerprint
Dive into the research topics of 'Two is better than one: Complementing oncolytic virotherapy with gemcitabine to potentiate antitumor immune responses'. Together they form a unique fingerprint.Cite this
Gujar, S. A., Clements, D., & Lee, P. W. K. (2014). Two is better than one: Complementing oncolytic virotherapy with gemcitabine to potentiate antitumor immune responses. OncoImmunology, 3(1), Article e27622. https://doi.org/10.4161/onci.27622